<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28076620</article-id><article-id pub-id-type="pmc">5407144</article-id><article-id pub-id-type="doi">10.5935/1678-9741.20160072</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Intraperitoneal Administration of Silymarin Protects End Organs from
Multivisceral Ischemia/Reperfusion Injury in a Rat Model</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ko&#x000e7;arslan</surname><given-names>Aydemir</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ko&#x000e7;arslan</surname><given-names>Sezen</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Aydin</surname><given-names>Mehmet Salih</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Gunay</surname><given-names>&#x0015e;amil</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Karahan</surname><given-names>Mahmut Alp</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Ta&#x0015f;k&#x00131;n</surname><given-names>Abdullah</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>&#x000dc;stunel</surname><given-names>Murat</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Aksoy</surname><given-names>Nurten</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff6">6</xref></contrib></contrib-group><aff id="aff1"><label>1</label> Kahramanmara&#x0015f; S&#x000fc;t&#x000e7;&#x000fc; Imam
University, Faculty of Medicine, Department of Cardiovascular Surgery,
Kahramanmara&#x0015f;, Turkey.</aff><aff id="aff2"><label>2</label> Kahramanmara&#x0015f; S&#x000fc;t&#x000e7;&#x000fc; Imam
University, Faculty of Medicine, Department of Pathology, Kahramanmara&#x0015f;,
Turkey.</aff><aff id="aff3"><label>3</label> Harran University, Faculty of Medicine, Department of
Cardiovascular Surgery, Sanliurfa, Turkey.</aff><aff id="aff4"><label>4</label> Harran University, Faculty of Medicine, Department of
Thoracic Surgery, Sanliurfa, Turkey.</aff><aff id="aff5"><label>5</label> Harran University, Faculty of Medicine, Department of
Anesthesia and Reanimation, Sanliurfa, Turkey.</aff><aff id="aff6"><label>6</label> Harran University, Faculty of Medicine, Department of
Biochemistry, Sanliurfa, Turkey.</aff><aff id="aff7"><label>7</label> &#x0015e;anl&#x00131;urfa Maternity Hospital, Department
of Biochemistry, Sanliurfa, Turkey.</aff><author-notes><corresp id="c1">Correspondence Address: Aydemir Ko&#x000e7;arslan,
Kahramanmara&#x0015f; S&#x000fc;t&#x000e7;&#x000fc; Imam University Faculty of
Medicine, Department of Cardiovascular Surgery, Kahramanmara&#x0015f;, Turkey -
Zip code: 46100. E-mail: <email>drakocarslan@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Nov-Dec</season><year>2016</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Nov-Dec</season><year>2016</year></pub-date><volume>31</volume><issue>6</issue><fpage>434</fpage><lpage>439</lpage><history><date date-type="received"><day>02</day><month>9</month><year>2016</year></date><date date-type="accepted"><day>11</day><month>10</month><year>2016</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>To determine whether intraperitoneal silymarin administration has favorable
effects on the heart, lungs, kidney, and liver and on oxidative stress in a
rat model of supraceliac aorta ischemia/reperfusion injury.</p></sec><sec><title>Methods</title><p>Thirty male Wistar albino rats were divided equally into three groups: sham,
control, and silymarin. The control and silymarin groups underwent
supraceliac aortic occlusion for 45 min, followed by a 60 min period of
reperfusion under terminal anesthesia. In the silymarin group, silymarin was
administered intraperitoneally during ischemia at a dose of 200 mg/kg. Rats
were euthanized using terminal anesthesia, and blood was collected from the
inferior vena cava for total antioxidant capacity, total oxidative status,
and oxidative stress index measurement. Lungs, heart, liver and kidney
tissues were histologically examined.</p></sec><sec><title>Results</title><p>Ischemia/reperfusion injury significantly increased histopathological damage
as well as the total oxidative status and oxidative stress index levels in
the blood samples. The silymarin group incurred significantly lesser damage
to the lungs, liver and kidneys than the control group, while no differences
were observed in the myocardium. Furthermore, the silymarin group had
significantly lower total oxidative status and oxidative stress index levels
than the control group.</p></sec><sec><title>Conclusion</title><p>Intraperitoneal administration of silymarin reduces oxidative stress and
protects the liver, kidney, and lungs from acute supraceliac abdominal aorta
ischemia/reperfusion injury in the rat model.</p></sec></abstract><kwd-group><kwd>Aorta/surgery</kwd><kwd>Reperfusion Injury</kwd><kwd>Silymarin</kwd><kwd>Rats</kwd><kwd>Wistar</kwd></kwd-group></article-meta></front><body><table-wrap id="t2" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup width="50%" span="1"><col span="1"/><col span="1"/></colgroup><thead><tr style="background-color:#e6e7e8"><th colspan="2" rowspan="1"><bold>Abbreviations, acronyms &#x00026; symbols</bold></th></tr></thead><tbody><tr style="background-color:#e6e7e8"><td rowspan="1" colspan="1">I/R</td><td rowspan="1" colspan="1">=Ischemia-Reperfusion</td></tr><tr style="background-color:#e6e7e8"><td rowspan="1" colspan="1">OSI</td><td rowspan="1" colspan="1">=Oxidative stress index</td></tr><tr style="background-color:#e6e7e8"><td rowspan="1" colspan="1">TAC</td><td rowspan="1" colspan="1">=Total antioxidant capacity</td></tr><tr style="background-color:#e6e7e8"><td rowspan="1" colspan="1">TOS</td><td rowspan="1" colspan="1">=Total oxidative status</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Acute supraceliac abdominal aorta ischemia may occur during treatment for abdominal
aortic aneurysms, dissection repair of acute thromboembolism with aortic
atherosclerosis, or trauma surgery. After reperfusion is performed, in such cases,
reactive oxygen species are generated and there is excess production of
pro-inflammatory molecules and a subsequent inflammatory response, which can lead to
damage to internal organs, such as the lungs, liver, kidneys, intestines and heart,
as well as death<sup>[</sup><sup><xref rid="r1" ref-type="bibr">1</xref></sup><sup>]</sup>. Multiple organ dysfunction occurring after
abdominal aortic surgery is one of the major causes of mortality and morbidity, with
25% of the deaths that occur after elective abdominal aortic repair being related to
multiple organ dysfunction<sup>[</sup><sup><xref rid="r2" ref-type="bibr">2</xref></sup><sup>]</sup>. Silymarin, which is a mixture of flavonoids and
polyphenols, has been shown to exhibit a variety of pharmacological activities as
well as antioxidant, anti-inflammatory, immunomodulatory, hepatoprotective,
neuroprotective, renoprotective [against ischemia-reperfusion (I/R) injury],
gastroprotective, antibacterial, antiviral, antithrombotic, and vasodilatory effects
in many experimental and clinical studies<sup>[</sup><sup><xref rid="r3" ref-type="bibr">3</xref></sup><sup>,</sup><sup><xref rid="r4" ref-type="bibr">4</xref></sup><sup>]</sup>. It reduces oxidative damage by balancing the
antioxidant status and regulating inflammatory mediators<sup>[</sup><sup><xref rid="r3" ref-type="bibr">3</xref></sup><sup>]</sup>. It has been reported
that silymarin reduces I/R damage in the heart, lungs, kidneys and liver, but there
are no studies on the preventive effects of silymarin in organs in the supraceliac
aorta I/R model<sup>[</sup><sup><xref rid="r3" ref-type="bibr">3</xref></sup><sup>-</sup><sup><xref rid="r5" ref-type="bibr">5</xref></sup><sup>]</sup>. The aim of this study is to examine silymarin's
protective effects on end organs (heart, lungs, liver and kidneys) in a rat model of
acute supraceliac aorta I/R.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Animals and Grouping</title><p>This experimental study was approved by the local ethics committee for animal
experiments (Dollvet Veterinary Vaccines Biological Substance Drug Production
Industry and Trade Inc. &#x0015e;anl&#x00131;urfa, Turkey). The experiments were
conducted on 30 three-month-old Wistar albino rats that ranged in weight from
200 g to 250 g. All the animals were kept under standard conditions and were
treated according to the guidelines of the National Institutes of Health. The
animals were kept in a 12h light/dark cycle (lights were turned on at 6 am). The
animals were deprived of food and water for 12h before surgery. The experiments
were conducted at the Dollvet Laboratory of Experimental Research.</p><p>The rats were randomly divided into three experimental groups: sham (n=10),
control (n=10) (I/R), and silymarin (n=10) (I/R-silymarin). They were
anesthetized intraperitoneally with xylazine (10 mg/kg) and ketamine
hydrochloride (50 mg/kg). The abdomens of the animals were shaved and then
cleaned with a povidone-iodine solution, and an abdominal midline incision was
made. In the sham group, only a laparotomy was carried out. In the control
group, a cross clamp was placed on the supraceliac aorta and ischemia was
applied for 45 min; this was followed by reperfusion for 60 min. In the
silymarin group, the cross-clamp was placed on the supraceliac aorta for 45 min,
and this was followed by reperfusion for 60 min. Silymarin was administered
during ischemia at a dose of 200 mg/kg via the intraperitoneal
route<sup>[</sup><sup><xref rid="r6" ref-type="bibr">6</xref></sup><sup>]</sup>. At the end of the study, blood samples were
obtained from the inferior vena cava of the rats, and heart, lung, liver and
kidney tissues were sampled and placed in formalin for pathological examination.
The blood samples obtained were centrifuged, and plasma was separated and stored
in the freezer at -80&#x000b0;C until biochemical analyses were performed. Silymarin
tablets were obtained from the pharmacy (Sigma-Aldrich, St. Louis, MO, USA). A
silymarin tablet of 85% purity was dissolved with 1% dimethyl sulfoxide before
it was administered.</p></sec><sec><title>Biochemical Tests</title><p>Serum levels of total oxidative status (TOS) and total antioxidant capacity (TAC)
were assessed using a new automated colorimetric measurement method developed by
Erel<sup>[</sup><sup><xref rid="r7" ref-type="bibr">7</xref></sup><sup>]</sup>, and calculated using the following formula:
Oxidative stress index (OSI, arbitrary units) = TOS (nmol
H<sub>2</sub>O<sub>2</sub> equiv/mg protein)/TAC (nmol Trolox equiv/mg
protein)<sup>[</sup><sup><xref rid="r8" ref-type="bibr">8</xref></sup><sup>]</sup>.</p></sec><sec><title>Histopathological Evaluation</title><p>The hearts, lungs, kidneys, and livers of the animals were harvested and fixed in
10% formaldehyde solution. After the specimens were embedded in paraffin and 5
&#x000b5;m sections had been cut, they were stained with hematoxylin and eosin
for light microscopic observation.</p><p>The prepared sections were examined under a light microscope at a magnification
of &#x000d7;20 (Olympus BX51 TF; Olympus, Melville, NY, USA). The samples were
then histologically graded according to the severity of the injury by using a
predetermined scoring system<sup>[</sup><sup><xref rid="r9" ref-type="bibr">9</xref></sup><sup>-</sup><sup><xref rid="r11" ref-type="bibr">11</xref></sup><sup>]</sup>. The histological indicators of I/R injury
in the kidney evaluation were tubular necrosis, interstitial edema, loss of
brush border, and cast formation. If there were no changes, a score of 0 was
assigned; if there were medium or mild changes, the score assigned was 1; and if
there were severe changes, the score was 2. The histological indicators of I/R
injury in the lung evaluation were alveolar congestion, intra-alveolar
hemorrhage, and interstitial perivascular infiltration of neutrophils. A score
of 0 was assigned when those characteristics were absent; 1 was assigned for
mild focal involvement; 2, for moderate focal involvement; and 3, for severely
marked lung involvement. In the histological examination of the heart,
interstitial edema, inflammatory cell infiltration, and coagulation necrosis
were considered as indicators of I/R injury. A score of 0 was assigned when no
changes were observed; 1 was assigned for slight focal involvement; 2, for
medium focal involvement; and 3, for severely marked involvement. In the
histopathological examination of the liver, nuclear pyknosis, necrosis,
neutrophil infiltration, and loss of intercellular borders were evaluated. A
score of 0 was assigned for minimal or no evidence of injury; grade 1, for mild
injury consisting of focal nuclear pyknosis; grade 2, for moderate to severe
injury, with extensive nuclear pyknosis and loss of intercellular borders; and
grade 3, for severe necrosis, with disintegration of hepatic cords and
neutrophil infiltration. The histopathological evaluation was conducted by the
same pathologist in a blinded manner.</p></sec><sec><title>Statistical Analysis</title><p>The data were analyzed using Statistical Package for the Social Sciences (SPSS
for Windows 11.5, Chicago, IL, USA). Continuous variables were presented as mean
&#x000b1; standard deviation, and discrete variables were presented using their
frequency or percentage distribution. The distribution of continuous variables
was examined using a one-sample Kolmogorov-Smirnov test, and it was found that
the data for all the groups were normally distributed. Therefore, non-parametric
independent group comparisons were made. For multiple comparisons, a
Kruskal-Wallis test was used, and for comparisons between groups, a Mann-Whitney
test was used if any statistical significance was found. A two-sided
<italic>P</italic> value of &#x0003c;0.05 was considered to indicate statistical
significance.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>All the animals were kept alive until the blood samples were taken. TAC activity was
higher in blood samples from the silymarin group than in samples from the sham and
control groups (<italic>P</italic>&#x0003c;0.001), but there was no statistically
significant difference between the sham and the control groups
(<italic>P</italic>&#x0003e;0.05) (<xref ref-type="table" rid="t1">Table 1</xref>, <xref ref-type="fig" rid="f1">Figure 1</xref>). Furthermore, TOS activity and OSI of
the control group were higher than in the sham and silymarin group
(<italic>P</italic>&#x0003c;0.001 for all comparisons) (<xref ref-type="table" rid="t1">Table 1</xref>, <xref ref-type="fig" rid="f2">Figures 2</xref> and
<xref ref-type="fig" rid="f3">3</xref>). The scores for tissue damage to the
kidney, lungs, liver, and heart are presented in <xref ref-type="table" rid="t1">Table 1</xref>. The scores for kidney, lungs and liver were significantly
higher in the control group than in the sham and silymarin groups
(<italic>P</italic>&#x0003c;0.05). In the histopathological examination of the sham
group, no changes were observed in the kidneys, lungs, liver (<xref ref-type="fig" rid="f4">Figures 4A</xref>, <xref ref-type="fig" rid="f4">4D</xref>, and <xref ref-type="fig" rid="f4">4G</xref>) or heart. Histopathological examination of
the control group revealed cast formation, brush border loss, and interstitial edema
in the kidney; intra-alveolar hemorrhage, interstitial perivascular infiltration of
neutrophils, and alveolar congestion in the lungs; and nuclear pyknosis, necrosis,
neutrophil infiltration, and loss of intercellular borders in the liver (<xref ref-type="fig" rid="f4">Figure 4B</xref>, <xref ref-type="fig" rid="f4">4E</xref>, and <xref ref-type="fig" rid="f4">4H</xref>). In the silymarin
group, fewer histopathological changes were observed in the kidneys, lungs and
livers than those in the control group (<xref ref-type="fig" rid="f4">Figure
4C</xref>, <xref ref-type="fig" rid="f4">4F</xref>, and <xref ref-type="fig" rid="f4">4I</xref>). No significant difference was observed in the
histopathological findings for the heart between all three groups under a light
microscope.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Sham, control and silymarin groups blood biochemistry and tissue
histopathological parameters.</p></caption><table frame="hsides" rules="all"><colgroup width="20%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th rowspan="2" align="left" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1"><bold>Sham Group</bold></th><th align="center" rowspan="1" colspan="1"><bold>Control Group</bold></th><th align="center" rowspan="1" colspan="1"><bold>Silymarin Group</bold></th><th align="center" rowspan="1" colspan="1"><bold><italic>P</italic></bold></th></tr><tr><th align="center" rowspan="1" colspan="1"><bold>n=10</bold></th><th align="center" rowspan="1" colspan="1"><bold>n=10</bold></th><th align="center" rowspan="1" colspan="1"><bold>n=10</bold></th><th align="center" rowspan="1" colspan="1"><bold>Kruskal-Wallis</bold></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">TAC</td><td align="center" rowspan="1" colspan="1">1.46&#x000b1;0.32</td><td align="center" rowspan="1" colspan="1">1.39&#x000b1;0.17</td><td align="center" rowspan="1" colspan="1">1.65&#x000b1;0.28<xref ref-type="table-fn" rid="TFN3">*</xref></td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">TOS</td><td align="center" rowspan="1" colspan="1">77.11+22.54</td><td align="center" rowspan="1" colspan="1">150.16&#x000b1;44.62<xref ref-type="table-fn" rid="TFN4">+</xref></td><td align="center" rowspan="1" colspan="1">55.81&#x000b1;17.25</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">OSI</td><td align="center" rowspan="1" colspan="1">5.22&#x000b1;0.81</td><td align="center" rowspan="1" colspan="1">10.63&#x000b1;2.01<xref ref-type="table-fn" rid="TFN4">+</xref></td><td align="center" rowspan="1" colspan="1">3.48&#x000b1;1.27</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Lung</td><td align="center" rowspan="1" colspan="1">2.2&#x000b1;0.4</td><td align="center" rowspan="1" colspan="1">6.2&#x000b1;1.2<xref ref-type="table-fn" rid="TFN4">+</xref></td><td align="center" rowspan="1" colspan="1">2.8&#x000b1;0.6</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Kidney</td><td align="center" rowspan="1" colspan="1">2.8&#x000b1;0.5</td><td align="center" rowspan="1" colspan="1">5&#x000b1;0.9<xref ref-type="table-fn" rid="TFN4">+</xref></td><td align="center" rowspan="1" colspan="1">3&#x000b1;0.7</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Liver</td><td align="center" rowspan="1" colspan="1">2.8&#x000b1;0.4</td><td align="center" rowspan="1" colspan="1">9.2&#x000b1;2.1<xref ref-type="table-fn" rid="TFN4">+</xref></td><td align="center" rowspan="1" colspan="1">3.8&#x000b1;0.7</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>TAC=total antioxidant capacity; TOS=total oxidant status; OSI=oxidative
stress index</p></fn><fn id="TFN2"><p><italic>P</italic>&#x0003c;0.05 was considered as statistically
significant.</p></fn><fn id="TFN3"><label>*</label><p><italic>P</italic>&#x0003c;0.001 (for all comparisons) compared with sham and
control group.</p></fn><fn id="TFN4"><label>+</label><p><italic>P</italic>&#x0003c;0.001 (for all comparisons) compared with sham and
silymarin group.</p></fn></table-wrap-foot></table-wrap><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>TAC levels for sham, control and silymarin groups. P&#x0003c;0.001 (for all
comparisons) compared with sham and control groups</p></caption><graphic xlink:href="rbccv-31-06-0434-g01"/></fig>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>TOS levels in sham, control and silymarin groups. P&#x0003c;0.001 (for all
comparisons) compared with sham and silymarin groups</p></caption><graphic xlink:href="rbccv-31-06-0434-g02"/></fig>
<fig id="f3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>OSI levels in sham, control and silymarin groups. P&#x0003c;0.001 (for all
comparisons) compared with sham and silymarin groups</p></caption><graphic xlink:href="rbccv-31-06-0434-g03"/></fig>
<fig id="f4" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>A, B, C are the kidney tissues of the sham, control and silymarin-treated
groups, respectively. D, E, F are the lung tissues of the sham, control
and silymarin-treated groups, respectively. G, H, I are the liver
tissues of the sham, control and silymarin-treated groups,
respectively.</p></caption><graphic xlink:href="rbccv-31-06-0434-g04"/></fig>
</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>In this experimental study, we observed the protective effects of silymarin in end
organs, such as the lungs, liver and kidneys, against aortic supraceliac I/R injury.
TOS and OSI values as well as histopathological damage scores were higher in the
control group than in the sham and silymarin groups.</p><p>During open surgery of the abdominal aorta, the placement of a cross-clamp at the
supraceliac level causes I/R damage to the bowel, kidneys, liver and lower limbs.
I/R results in the transport of either bacteria or endotoxins across the intestinal
mucosal barrier, leakage of reactive oxygen species and inflammatory cytokines into
systemic circulation, kidney tubule damage, kidney failure, and acute damage to the
lungs, liver and other internal organs<sup>[</sup><sup><xref rid="r12" ref-type="bibr">12</xref></sup><sup>]</sup>. It has been reported that various
plant extracts have protective effects against I/R damage. Silymarin is one of them.
Silymarin is derived from dry thistle seeds (<italic>Silybum marianum</italic>).
Milk thistle is the oldest and best studied plant in the treatment of liver
diseases, with the first records of its therapeutic effects being found in the Old
Testament<sup>[</sup><sup><xref rid="r3" ref-type="bibr">3</xref></sup><sup>]</sup>. A standard silymarin dry extract is a bioflavonoid
complex that consists of at least seven flavonolignans. The seven main components of
silymarin are taxifolin, silychristin, silydianin, silybin A, silybin B, iso-silybin
A, and iso-silybin B. Taxifolin is the only isomer in the silymarin extract that is
not a flavonolignan and has strong antioxidant activity<sup>[</sup><sup><xref rid="r3" ref-type="bibr">3</xref></sup><sup>]</sup>. Silybin is the main
component of this complex extract, accounting for 60-70% of the constituents; it is
a potent inhibitor of nuclear factor kappa B (NF-kB) activation, and it is induced
by a variety of anti-inflammatory agents<sup>[</sup><sup><xref rid="r13" ref-type="bibr">13</xref></sup><sup>]</sup>. It has been reported that the
anti-inflammatory and anti-cancer effects of silymarin and other flavonolignans are
related to their potency inhibition of NF-kB. This transcription factor is involved
in the arrangement of several genes associated with immune function, inflammation
stress response, cell differentiation, apoptosis and cell survival, which are
required for cancer development and progression<sup>[</sup><sup><xref rid="r14" ref-type="bibr">14</xref></sup><sup>]</sup>. Silymarin superoxide
ions act in a similar manner to hydroxyl radicals, hypochlorous acid, and singlet
molecular oxygen collectors<sup>[</sup><sup><xref rid="r15" ref-type="bibr">15</xref></sup><sup>]</sup>. It increases the level of cellular glutathione
and reduces tumor promoter activity<sup>[</sup><sup><xref rid="r16" ref-type="bibr">16</xref></sup><sup>]</sup>. In addition, silymarin inhibits lipid
peroxidation and reduces free radicaldependent tissue damage<sup>[</sup><sup><xref rid="r17" ref-type="bibr">17</xref></sup><sup>]</sup>. It has also been
shown that silymarin increases the activity of antioxidant enzymes, such as
superoxide dismutase, glutathione peroxidase and catalase, in the pancreas of
rats<sup>[</sup><sup><xref rid="r18" ref-type="bibr">18</xref></sup><sup>]</sup>.</p><p>Rao &#x00026; Viswanath<sup>[</sup><sup><xref rid="r19" ref-type="bibr">19</xref></sup><sup>]</sup> found that oral silymarin use as phytomedicine has
cardioprotective properties against I/R-induced myocardial infarction in rats, and
the myocardial protective effects of silymarin have also been demonstrated in
cardiac injury induced by anthracycline, cisplatin, doxorubicin, adriamycin, and
sodium fluoride in rats<sup>[</sup><sup><xref rid="r3" ref-type="bibr">3</xref></sup><sup>]</sup>. In our study, the heart I/R injury associated with
distant organ damage could not be observed under a light microscope; this is
probably related to the short retention time of reperfusion. However, Altaei et
al.<sup>[</sup><sup><xref rid="r20" ref-type="bibr">20</xref></sup><sup>]</sup>
have shown that oral silymarin treatment before surgery protects the heart against
reperfusion injury and inflammation through anti-inflammatory and antioxidant
activity during CABG surgery in humans.</p><p>Several studies have reported the protective effects of silymarin in the lungs in
different situations and via different mechanisms. Jin et al.<sup>[</sup><sup><xref rid="r21" ref-type="bibr">21</xref></sup><sup>]</sup> showed that oral
silymarin treatment was able to improve pulmonary vascular dysfunction following
lung I/R injury via the HIF-1&#x003b1;-iNOS pathway. Sharma et
al.<sup>[</sup><sup><xref rid="r22" ref-type="bibr">22</xref></sup><sup>]</sup> showed that silibinin significantly stimulates
growth inhibition, moderate cell-cycle arrest and apoptotic death in both small-cell
and non-small cell human lung carcinoma cells. The pulmonary protective effects of
silymarin against I/R injury via intraperitoneal route have been shown in this study
for the first time. The renoprotective effects of silymarin have also been discussed
in several studies, including in nephrotoxic drugs in rats<sup>[</sup><sup><xref rid="r23" ref-type="bibr">23</xref></sup><sup>-</sup><sup><xref rid="r25" ref-type="bibr">25</xref></sup><sup>]</sup>. Oral silymarin use
has also been studied in different kidney I/R models, and is reported to have
favorable effects with different potential mechanisms, including primarily
antioxidant mechanisms<sup>[</sup><sup><xref rid="r26" ref-type="bibr">26</xref></sup><sup>,</sup><sup><xref rid="r27" ref-type="bibr">27</xref></sup><sup>]</sup>. Likewise, in our study, the histopathological
findings showed that intraperitoneal silymarin use has renoprotective effects
against I/R injury.</p><p>Several studies have shown that silymarin has protective effects against I/R injury
to the liver, and that silymarin can also protect the liver against hepatotoxic
drugs and liver cancer<sup>[</sup><sup><xref rid="r28" ref-type="bibr">28</xref></sup><sup>]</sup>. In a study by Ligeret et al.<sup>[</sup><sup><xref rid="r29" ref-type="bibr">29</xref></sup><sup>]</sup>, it was reported that
a preservation solution with silibinin has protective effects against cold
preservation-warm reperfusion injury on experimental liver transplantation.
Additionally, Wu et al.<sup>[</sup><sup><xref rid="r30" ref-type="bibr">30</xref></sup><sup>]</sup> showed that intravenous silymarin use protects
liver against I/R injury. Our study has also provided histopathological evidence for
the protection of the liver against I/R injury by intraperitoneal administration of
silymarin. Thus, in this study, we observed the protective effects of silymarin in
the lungs, kidneys and liver through histopathological evaluation. The significant
oxidative stress in the control group when compared to the sham and silymarin groups
also emphasizes the antioxidant properties of silymarin, which may serve as a
protective mechanism in the rat acute supraceliac abdominal aorta I/R model.</p><p>We believe that there are sufficient preclinical research findings about the
molecular antioxidant, anti-inflammatory, and anti-cancer effects of silymarin, as
well as its drug toxicity, bioavailability, pharmacokinetics, and novel drug
delivery approaches<sup>[</sup><sup><xref rid="r3" ref-type="bibr">3</xref></sup><sup>]</sup>. Still, the clinical implications and appropriate
pathophysiological mechanisms underlying its effects need to be elucidated in
large-scale clinical studies.</p><p>The limitations of this study are as follows: the effect of oral intake of silymarin
in rats has not been evaluated. Another limitation is that the biochemical markers
urea, creatinine, creatinine phosphokinase, creatinine kinase-myocardial band,
aspartate aminotransferase, and alanine aminotransferase have not been examined.
Moreover, the effects of silymarin on the intestines, the spinal cord, and the brain
have not been studied either.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>In conclusion, silymarin has cardioprotective, renoprotective, neuroprotective,
pulmonary protective, anti-inflammatory, antioxidant, immunomodulatory,
anti-proliferative, hepatoprotective and antidiabetic effects that have been
demonstrated in clinical and experimental studies. Despite our limitations, this
study has shown that the administration of silymarin through the intraperitoneal
route reduces histopathological damage to the liver, kidneys and lungs, as well as
oxidative stress in the I/R model of the supraceliac abdominal aorta for the first
time. The findings indicate that silymarin treatment may reduce tissue damage and
OSI. They therefore lay the foundation for future clinical trials on the efficacy of
silymarin.</p><table-wrap id="t3" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup width="50%" span="1"><col span="1"/><col span="1"/></colgroup><thead><tr><th colspan="2" align="left" rowspan="1"><bold>Authors' roles &#x00026;
responsibilities</bold></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">AK</td><td align="left" rowspan="1" colspan="1">Analysis and /or interpretation of data, statistical
analysis, final approval of the manuscript, conception and study
design, conduct of procedures and/or experiments, writing of the
manuscript or review of its content</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SK</td><td align="left" rowspan="1" colspan="1">Analysis and/or interpretation of data, final approval
of manuscript</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MSA</td><td align="left" rowspan="1" colspan="1">Statistical analysis, conception and study design,
conduct of procedures and/or experiments</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x0015e;G</td><td align="left" rowspan="1" colspan="1">Conduct of procedures and/or experiments, writing of
the manuscript or review of its content</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MAK</td><td align="left" rowspan="1" colspan="1">Statistical analysis, final approval of manuscript</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AT</td><td align="left" rowspan="1" colspan="1">Statistical analysis, final approval of the manuscript,
conception and study design, conduct of procedures and/ or
experiments</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MU</td><td align="left" rowspan="1" colspan="1">Statistical analysis, final approval of the manuscript,
writing of the manuscript or review of its content</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">Writing of the manuscript or review of its content</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn><fn fn-type="other"><p>This study was carried out at Kahramanmara&#x0015f; S&#x000fc;t&#x000e7;&#x000fc;
Imam University, Faculty of Medicine, Department of Cardiovascular Surgery,
Kahramanmara&#x0015f;, Turkey.</p></fn><fn fn-type="supported-by"><p>No financial support.</p></fn></fn-group><ref-list><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tapuria</surname><given-names>N</given-names></name><name><surname>Kumar</surname><given-names>Y</given-names></name><name><surname>Habib</surname><given-names>MM</given-names></name><name><surname>Abu Amara</surname><given-names>M</given-names></name><name><surname>Seifalian</surname><given-names>AM</given-names></name><name><surname>Davidson</surname><given-names>BR</given-names></name></person-group><article-title>Remote ischemic preconditioning: a novel protective method from
ischemia reperfusion injury -a review</article-title><source>J Surg Res</source><year>2008</year><volume>150</volume><issue>2</issue><fpage>304</fpage><lpage>330</lpage><pub-id pub-id-type="pmid">19040966</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>YS</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Wen</surname><given-names>SH</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Limb remote ischemic preconditioning for intestinal and pulmonary
protection during elective open infrarenal abdominal aortic aneurysm repair:
a randomized controlled trial</article-title><source>Anesthesiology</source><year>2013</year><volume>118</volume><issue>4</issue><fpage>842</fpage><lpage>852</lpage><pub-id pub-id-type="pmid">23353795</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mili&#x00107;</surname><given-names>N</given-names></name><name><surname>Milosevi&#x00107;</surname><given-names>N</given-names></name><name><surname>Suvajdzi&#x00107;</surname><given-names>L</given-names></name><name><surname>Zarkov</surname><given-names>M</given-names></name><name><surname>Abenavoli</surname><given-names>L</given-names></name></person-group><article-title>New therapeutic potentials of milk thistle (Silybum
marianum)</article-title><source>Nat Prod Commun</source><year>2013</year><volume>8</volume><issue>12</issue><fpage>1801</fpage><lpage>1810</lpage><pub-id pub-id-type="pmid">24555302</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>Z</given-names></name><name><surname>Dumas</surname><given-names>TE</given-names></name><name><surname>Schrieber</surname><given-names>SJ</given-names></name><name><surname>Hawke</surname><given-names>RL</given-names></name><name><surname>Fried</surname><given-names>MW</given-names></name><name><surname>Smith</surname><given-names>PC</given-names></name></person-group><article-title>Pharmacokinetics and metabolic profile of free, conjugated, and
total silymarin flavonolignans in human plasma after oral administration of
milk thistle extract</article-title><source>Drug Metab Dispos</source><year>2008</year><volume>36</volume><issue>1</issue><fpage>65</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">17913795</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altuner</surname><given-names>D</given-names></name><name><surname>Cetin</surname><given-names>N</given-names></name><name><surname>Suleyman</surname><given-names>B</given-names></name><name><surname>Aslan</surname><given-names>Z</given-names></name><name><surname>Hacimuftuoglu</surname><given-names>A</given-names></name><name><surname>Gulaboglu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effect of thiamine pyrophosphate on ischemia-reperfusion induced
oxidative damage in rat kidney</article-title><source>Indian J Pharmacol</source><year>2013</year><volume>45</volume><issue>4</issue><fpage>339</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">24014907</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Najafzadeh</surname><given-names>H</given-names></name><name><surname>Razi Jalali</surname><given-names>MR</given-names></name><name><surname>Morovvati</surname><given-names>H</given-names></name><name><surname>Taravati</surname><given-names>F</given-names></name></person-group><article-title>Comparison of the prophylactic effect of silymarin and
deferoxamine on iron overloadinduced hepatotoxicity in rat</article-title><source>J Med Toxicol</source><year>2010</year><volume>6</volume><issue>1</issue><fpage>22</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">20182837</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erel</surname><given-names>O</given-names></name></person-group><article-title>A novel automated method to measure total antioxidant response
against potent free radical reactions</article-title><source>Clin Biochem</source><year>2004</year><volume>37</volume><issue>2</issue><fpage>112</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">14725941</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erel</surname><given-names>O</given-names></name></person-group><article-title>A new automated colorimetric method for measuring total oxidant
status</article-title><source>Clin Biochem</source><year>2005</year><volume>38</volume><issue>12</issue><fpage>1103</fpage><lpage>1111</lpage><pub-id pub-id-type="pmid">16214125</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solez</surname><given-names>K</given-names></name><name><surname>Morel-Maroger</surname><given-names>L</given-names></name><name><surname>Sraer</surname><given-names>JD</given-names></name></person-group><article-title>The morphology of "acute tubular necrosis" in man: analysis of 57
renal biopsies and a comparison with the glycerol model</article-title><source>Medicine (Baltimore)</source><year>1979</year><volume>58</volume><issue>5</issue><fpage>362</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">481195</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aydin</surname><given-names>MS</given-names></name><name><surname>Caliskan</surname><given-names>A</given-names></name><name><surname>Kocarslan</surname><given-names>A</given-names></name><name><surname>Kocarslan</surname><given-names>S</given-names></name><name><surname>Yildiz</surname><given-names>A</given-names></name><name><surname>G&#x000fc;nay</surname><given-names>S</given-names></name><etal/></person-group><article-title>Intraperitoneal curcumin decreased lung, renal and heart injury
in abdominal aorta ischemia/reperfusion model in rat</article-title><source>Int J Surg</source><year>2014</year><volume>12</volume><issue>6</issue><fpage>601</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">24815029</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000f6;zen</surname><given-names>S</given-names></name><name><surname>K&#x00131;sak&#x000fc;rek</surname><given-names>M</given-names></name><name><surname>Y&#x00131;ld&#x00131;z</surname><given-names>F</given-names></name><name><surname>G&#x000f6;n&#x000fc;ltas</surname><given-names>M</given-names></name><name><surname>Din&#x000e7;el</surname><given-names>AS</given-names></name></person-group><article-title>The effects of glutamine on hepatic ischemia reperfusion injury
in rats</article-title><source>Hippokratia</source><year>2011</year><volume>15</volume><issue>2</issue><fpage>161</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">22110300</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Granger</surname><given-names>DN</given-names></name><name><surname>Kvietys</surname><given-names>PR</given-names></name></person-group><article-title>Reperfusion injury and reactive oxygen species: the evolution of
a concept</article-title><source>Redox Biol</source><year>2015</year><volume>6</volume><fpage>524</fpage><lpage>551</lpage><pub-id pub-id-type="pmid">26484802</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manna</surname><given-names>SK</given-names></name><name><surname>Mudkopadhyay</surname><given-names>A</given-names></name><name><surname>Van</surname><given-names>NT</given-names></name><name><surname>Aggarwal</surname><given-names>BB</given-names></name></person-group><article-title>Silymarin suppresses TNF-induced activation of NF-kappaB, c-Jun
N-terminal kinase, and apoptosis</article-title><source>J Immunol</source><year>1999</year><volume>163</volume><issue>12</issue><fpage>6800</fpage><lpage>6809</lpage><pub-id pub-id-type="pmid">10586080</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarkar</surname><given-names>FH</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Kong</surname><given-names>D</given-names></name></person-group><article-title>NF-kappaB signaling pathway and its therapeutic implications in
human diseases</article-title><source>Int Rev Immunol</source><year>2008</year><volume>27</volume><issue>5</issue><fpage>293</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">18853341</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mira</surname><given-names>L</given-names></name><name><surname>Silva</surname><given-names>M</given-names></name><name><surname>Manso</surname><given-names>CF</given-names></name></person-group><article-title>Scavenging of reactive oxygen species by silibinin
dihemisuccinate</article-title><source>Biochem Pharmacol</source><year>1994</year><volume>48</volume><issue>4</issue><fpage>753</fpage><lpage>759</lpage><pub-id pub-id-type="pmid">8080448</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vargas-Mendoza</surname><given-names>N</given-names></name><name><surname>Madrigal-Santill&#x000e1;n</surname><given-names>E</given-names></name><name><surname>Morales-Gonz&#x000e1;lez</surname><given-names>A</given-names></name><name><surname>Esquivel-Soto</surname><given-names>J</given-names></name><name><surname>Esquivel-Chirino</surname><given-names>C</given-names></name><name><surname>Garc&#x000ed;a-Luna</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Hepatoprotective effect of silymarin</article-title><source>World J Hepatol</source><year>2014</year><volume>6</volume><issue>3</issue><fpage>144</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">24672644</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosisio</surname><given-names>E</given-names></name><name><surname>Benelli</surname><given-names>C</given-names></name><name><surname>Pirola</surname><given-names>O</given-names></name></person-group><article-title>Effect of the flavanolignans of <italic>Silybum marianum</italic>
L. on lipid peroxidation in rat liver microsomes and freshly isolated
hepatocytes</article-title><source>Pharmacol Res</source><year>1992</year><volume>25</volume><issue>2</issue><fpage>147</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">1635893</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soto</surname><given-names>C</given-names></name><name><surname>Recoba</surname><given-names>R</given-names></name><name><surname>Barr&#x000f3;n</surname><given-names>H</given-names></name><name><surname>Alvarez</surname><given-names>C</given-names></name><name><surname>Favari</surname><given-names>L</given-names></name></person-group><article-title>Silymarin increases antioxidant enzymes in alloxan-induced
diabetes in rat pancreas</article-title><source>Comp Biochem Physiol C Toxicol Pharmacol</source><year>2003</year><volume>136</volume><issue>3</issue><fpage>205</fpage><lpage>212</lpage><pub-id pub-id-type="pmid">14659454</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>PR</given-names></name><name><surname>Viswanath</surname><given-names>RK</given-names></name></person-group><article-title>Cardioprotective activity of silymarin in
ischemia-reperfusion-induced myocardial infarction in albino
rats</article-title><source>Exp Clin Cardiol</source><year>2007</year><volume>12</volume><issue>4</issue><fpage>179</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">18651002</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altaei</surname><given-names>DT</given-names></name><name><surname>Dilshad</surname><given-names>DD</given-names></name><name><surname>Jamal</surname><given-names>DIA</given-names></name></person-group><article-title>The cardioprotection of silymarin in coronary artery bypass
grafting surgery</article-title><source>Intech</source><year>2013</year><volume>14</volume><fpage>239</fpage><lpage>249</lpage></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Lu</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name></person-group><article-title>Modulatory effect of silymarin on pulmonary vascular dysfunction
through HIF-1&#x003b1;-iNOS following rat lung ischemia-reperfusion
injury</article-title><source>Exp Ther Med</source><year>2016</year><volume>12</volume><issue>2</issue><fpage>1135</fpage><lpage>1140</lpage><pub-id pub-id-type="pmid">27446333</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>G</given-names></name><name><surname>Singh</surname><given-names>RP</given-names></name><name><surname>Chan</surname><given-names>DC</given-names></name><name><surname>Agarwal</surname><given-names>R</given-names></name></person-group><article-title>Silibinin induces growth inhibition and apoptotic cell death in
human lung carcinoma cells</article-title><source>Anticancer Res</source><year>2003</year><volume>23</volume><issue>3B</issue><fpage>2649</fpage><lpage>2655</lpage><pub-id pub-id-type="pmid">12894553</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karimi</surname><given-names>G</given-names></name><name><surname>Ramezani</surname><given-names>M</given-names></name><name><surname>Tahoonian</surname><given-names>Z</given-names></name></person-group><article-title>Cisplatin nephrotoxicity and protection by milk thistle extract
in rats</article-title><source>Evid Based Complement Alternat Med</source><year>2005</year><volume>2</volume><issue>3</issue><fpage>383</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">16136217</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname><given-names>G</given-names></name><name><surname>Athar</surname><given-names>M</given-names></name><name><surname>Alam</surname><given-names>MS</given-names></name></person-group><article-title>Dietary supplementation of silymarin protects against chemically
induced nephrotoxicity, inflammation and renal tumor promotion
response</article-title><source>Invest New Drugs</source><year>2010</year><volume>28</volume><issue>5</issue><fpage>703</fpage><lpage>713</lpage><pub-id pub-id-type="pmid">19590824</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Shitany</surname><given-names>NA</given-names></name><name><surname>El-Haggar</surname><given-names>S</given-names></name><name><surname>El-desoky</surname><given-names>K</given-names></name></person-group><article-title>Silymarin prevents adriamycininduced cardiotoxicity and
nephrotoxicity in rats</article-title><source>Food ChemToxicol</source><year>2008</year><volume>46</volume><issue>7</issue><fpage>2422</fpage><lpage>2428</lpage></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turgut</surname><given-names>F</given-names></name><name><surname>Bayrak</surname><given-names>O</given-names></name><name><surname>Catal</surname><given-names>F</given-names></name><name><surname>Bayrak</surname><given-names>R</given-names></name><name><surname>Atmaca</surname><given-names>AF</given-names></name><name><surname>Koc</surname><given-names>A</given-names></name><etal/></person-group><article-title>Antioxidant and protective effects of silymarin on ischemia and
reperfusion injury in the kidney tissues of rats</article-title><source>Int Urol Nephrol</source><year>2008</year><volume>40</volume><issue>2</issue><fpage>453</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">18368506</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Cui</surname><given-names>F</given-names></name></person-group><article-title>Protective role of silymarin in a mouse model of renal
ischemia-reperfusion injury</article-title><source>Diagn Pathol</source><year>2015</year><volume>10</volume><fpage>198</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">26521234</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>Recent advances in natural products from plants for treatment of
liver diseases</article-title><source>Eur J Med Chem</source><year>2013</year><volume>63</volume><fpage>570</fpage><lpage>577</lpage><pub-id pub-id-type="pmid">23567947</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ligeret</surname><given-names>H</given-names></name><name><surname>Brault</surname><given-names>A</given-names></name><name><surname>Vallerand</surname><given-names>D</given-names></name><name><surname>Haddad</surname><given-names>Y</given-names></name><name><surname>Haddad</surname><given-names>PS</given-names></name></person-group><article-title>Antioxidant and mitochondrial protective effects of silibinin in
cold preservation-warm reperfusion liver injury</article-title><source>J Ethnopharmacol</source><year>2008</year><volume>115</volume><issue>3</issue><fpage>507</fpage><lpage>514</lpage><pub-id pub-id-type="pmid">18061382</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>CG</given-names></name><name><surname>Chamuleau</surname><given-names>RA</given-names></name><name><surname>Bosch</surname><given-names>KS</given-names></name><name><surname>Frederiks</surname><given-names>WM</given-names></name></person-group><article-title>Protective effect of silymarin on rat liver injury induced by
ischemia</article-title><source>Virchows Arch B Cell Pathol Incl Mol Pathol</source><year>1993</year><volume>64</volume><issue>5</issue><fpage>259</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">8287122</pub-id></element-citation></ref></ref-list></back></article>